SYROS PHARMACEUTICALS INC (SYRS)

Company Profile

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 117 full-time employees. The company went IPO on 2016-06-30. The firm is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. Its lead product candidates include Tamibarotene and SY-2101. Its Tamibarotene, is a selective retinoic acid receptor alpha (RARα), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Its SY-2101, is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL). The Company’s product candidate also includes SY-5609, which is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) which is being developed for patients with select solid tumors and in combination with gemcitabine and with gemcitabine plus nab-paclitaxel in patients with metastatic pancreatic cancer. The company is also focused on the development for the treatment of multiple preclinical programs in oncology.

Company Info

SYROS PHARMACEUTICALS INC

35 Cambridge Park Drive

Cambridge MASSACHUSETTS 02140

P: 16177441340

CEO: Nancy Simonian

Employees: 117

Website: https://syros.com/